Market Closed -
Nasdaq
04:00:00 2024-05-22 pm EDT
|
5-day change
|
1st Jan Change
|
7.9
USD
|
+0.51%
|
|
-9.71%
|
+4.94%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
744.1
|
1,057
|
172.7
|
57.79
|
76.05
|
164
|
-
|
-
|
Enterprise Value (EV)
1 |
578
|
626.9
|
-132.4
|
-127.8
|
-20.47
|
15.24
|
28.46
|
164
|
P/E ratio
|
-11.4
x
|
-7.86
x
|
-1.19
x
|
-0.37
x
|
-0.65
x
|
-1.26
x
|
-1.38
x
|
-1.46
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,976
x
|
-
|
23
x
|
-
|
21.1
x
|
687
x
|
18.6
x
|
13.3
x
|
EV / Revenue
|
2,312
x
|
-
|
-17.7
x
|
-
|
-5.69
x
|
63.8
x
|
3.23
x
|
13.3
x
|
EV / EBITDA
|
-8.63
x
|
-5.51
x
|
0.94
x
|
0.85
x
|
0.17
x
|
-0.14
x
|
-0.15
x
|
-0.85
x
|
EV / FCF
|
-8.45
x
|
-6.88
x
|
1.08
x
|
1.07
x
|
0.22
x
|
-0.14
x
|
-0.37
x
|
-0.94
x
|
FCF Yield
|
-11.8%
|
-14.5%
|
92.8%
|
93.8%
|
448%
|
-701%
|
-274%
|
-106%
|
Price to Book
|
4.22
x
|
2.12
x
|
0.55
x
|
0.32
x
|
0.91
x
|
1.25
x
|
1.55
x
|
-
|
Nbr of stocks (in thousands)
|
6,459
|
9,748
|
9,815
|
9,973
|
10,103
|
20,757
|
-
|
-
|
Reference price
2 |
115.2
|
108.4
|
17.60
|
5.795
|
7.528
|
7.900
|
7.900
|
7.900
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/29/22
|
3/30/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.25
|
-
|
7.5
|
-
|
3.6
|
0.2387
|
8.798
|
12.3
|
EBITDA
1 |
-66.97
|
-113.8
|
-141.5
|
-150.6
|
-118.3
|
-111
|
-184
|
-193
|
EBIT
1 |
-68.54
|
-118
|
-146.1
|
-157.1
|
-124
|
-116.5
|
-150.9
|
-178.9
|
Operating Margin
|
-27,418%
|
-
|
-1,948.29%
|
-
|
-3,444.19%
|
-48,804.41%
|
-1,714.82%
|
-1,454.18%
|
Earnings before Tax (EBT)
1 |
-64.49
|
-116.4
|
-145.5
|
-154.5
|
-118.2
|
-122.6
|
-140.4
|
-172.1
|
Net income
1 |
-64.49
|
-117.5
|
-145.5
|
-154.5
|
-117.2
|
-119.5
|
-147.2
|
-175.9
|
Net margin
|
-25,794.4%
|
-
|
-1,940.53%
|
-
|
-3,254.58%
|
-50,054.46%
|
-1,673.27%
|
-1,429.73%
|
EPS
2 |
-10.10
|
-13.80
|
-14.80
|
-15.60
|
-11.60
|
-6.262
|
-5.716
|
-5.424
|
Free Cash Flow
1 |
-68.42
|
-91.14
|
-123
|
-119.9
|
-91.71
|
-106.8
|
-77.91
|
-174.5
|
FCF margin
|
-27,366.8%
|
-
|
-1,639.39%
|
-
|
-2,547.5%
|
-44,742.16%
|
-885.53%
|
-1,418.4%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/29/22
|
3/30/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
3.6
|
-
|
-
|
-
|
-
|
0.0757
|
0.0796
|
0.0834
|
-
|
-
|
EBITDA
1 |
-33.1
|
-36.71
|
-42.42
|
-39.25
|
-32.23
|
-28.65
|
-31.53
|
-33.02
|
-25.15
|
-25.84
|
-27
|
-28
|
-29
|
-34
|
-42
|
EBIT
1 |
-34.42
|
-38.13
|
-44.02
|
-41.04
|
-33.94
|
-30.24
|
-33.06
|
-34.53
|
-26.16
|
-26.84
|
-29.83
|
-31.27
|
-32.78
|
-33.88
|
-38.62
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-839.97%
|
-
|
-
|
-
|
-
|
-39,399.68%
|
-39,296%
|
-39,295.61%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-34.41
|
-37.89
|
-43.74
|
-40.11
|
-32.72
|
-29.04
|
-31.49
|
-32.87
|
-24.85
|
-24.79
|
-30.21
|
-31.98
|
-33.6
|
-31.5
|
-33
|
Net income
1 |
-34.41
|
-37.91
|
-43.76
|
-40.13
|
-32.74
|
-29.06
|
-31.51
|
-32.88
|
-23.71
|
-24.79
|
-29.57
|
-31.19
|
-32.48
|
-32.62
|
-37.38
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-807.11%
|
-
|
-
|
-
|
-
|
-39,056.66%
|
-39,198.94%
|
-38,931.08%
|
-
|
-
|
EPS
2 |
-3.500
|
-3.800
|
-4.400
|
-4.000
|
-3.300
|
-2.900
|
-3.100
|
-3.300
|
-2.300
|
-1.500
|
-1.542
|
-1.570
|
-1.572
|
-1.765
|
-2.010
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/30/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/18/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
166
|
430
|
305
|
186
|
96.5
|
149
|
136
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-68.4
|
-91.1
|
-123
|
-120
|
-91.7
|
-107
|
-77.9
|
-174
|
ROE (net income / shareholders' equity)
|
-
|
-38.6%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
27.30
|
51.00
|
32.30
|
18.10
|
8.280
|
6.300
|
5.100
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
19.2
|
11.8
|
15.1
|
11.8
|
0.81
|
0.57
|
0.74
|
0.72
|
Capex / Sales
|
7,698.8%
|
-
|
201.64%
|
-
|
22.44%
|
239.62%
|
8.43%
|
5.82%
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/29/22
|
3/30/23
|
3/18/24
|
-
|
-
|
-
|
Average target price
35.33
USD Spread / Average Target +347.26% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.94% | 164M | | +9.99% | 115B | | +12.01% | 106B | | -3.07% | 24.69B | | -1.08% | 21.97B | | -5.34% | 19.27B | | -6.90% | 17.56B | | -39.36% | 17.32B | | +5.82% | 14.03B | | +33.05% | 12.13B |
Bio Therapeutic Drugs
|